Raphael J. Landovitz, MD, MSc

Raphael Landovitz, MD, MSc, is Professor of Medicine at the UCLA Center for Clinical AIDS Research & Education. He is also the Center Director of CHIPTS. He has led combination prevention intervention studies and projects using Post-Exposure (PEP) and Pre-Exposure (PrEP) strategies for MSM and TGW, as well as being part of leadership groups of the DAIDS-funded AIDS Clinical Trial Groups (ACTG), HIV Prevention Trial Network (HPTN), and former adolescent Trial Network (ATN). He recently completed a term as chair of the ACTG Antiretroviral Strategies Scientific Committee, is the principal investigator of two multisite PrEP demonstration project in Los Angeles County, and leads the NIH/DAIDS-funded Phase 2 and Phase 3 registrational clinical trials evaluating long-acting injectable Cabotegravir for PrEP. He serves on the Executive Committee of the HIV Prevention Trials Network, and was awarded the HIVMA HIV Research Award in 2017. His research agenda focuses on the optimization of the use of antiretroviral medication for both HIV treatment and HIV prevention.

1. Hanscom, B., Marzinke, M. A., Li, X., Donnell, D., Bies, R., Hendrix, C. W., Wang, Z., Acuipil, C., Rinehart, A., Collins, J. W., Rooney, J. F., Soto Torres, L., Richardson, P., Chariyalerstsak, S., Valdez Ramalho Madruga, J., Hurt, C. B., Magnus, M., Frank, I., McCauley, M., Grinsztejn, B., … Landovitz, R. J. (2025). Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083. The Journal of infectious diseases, jiaf561. Advance online publication.

---